Hepion pharmaceuticals announces management changes

Edison, n.j., sept. 06, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, announced that stephen harrison, m.d., has been appointed as consultant medical director. dr. harrison, the current chairman of hepion's scientific advisory board (“sab”), succeeds todd hobbs, m.d., who has provided notice to the company of his resignation as chief medical officer, effective september 29, 2023.
HEPA Ratings Summary
HEPA Quant Ranking